Cover Image
市場調查報告書

非小細胞肺癌 (NSCLC) 治療藥的全球市場的預測:化療、EGFR&ALK抑制劑、VEGF/VEGFR抑制劑、免疫療法、其他

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other

出版商 Visiongain Ltd 商品編碼 342591
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非小細胞肺癌 (NSCLC) 治療藥的全球市場的預測:化療、EGFR&ALK抑制劑、VEGF/VEGFR抑制劑、免疫療法、其他 Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other
出版日期: 2017年06月29日 內容資訊: 英文 172 Pages
簡介

本報告提供全球非小細胞肺癌 (NSCLC) 治療藥的市場調查,NSCLC與其治療方法相關概要,主要的已上市藥物的作用機制、市場趨勢、收益預測,研發產品線趨勢及展望,市場促進因素、阻礙要素分析,各治療區分及各主要國家的市場成長預測等彙整資料。

第1章 報告概要

第2章 與簡介:NSCLC其治療

  • 最常見的癌症肺癌、其多數為NSCLC
  • 3種主要的組織學的分類
  • 遺傳基因突變和標靶治療
  • NSCLC的階段
  • 治療方案:各階段

第3章 主要NSCLC治療藥的展望

  • Alimta (Pemetrexed):Eli Lilly
  • Avastin (Bevacizumab):Roche
  • Tarceva (Erlotinib):Roche
  • Iressa (Gefitinib):AstraZeneca
  • Gilotrif (Afatinib):Boehringer Ingelheim
  • Xalkori (Crizotinib):Pfizer
  • Abraxane (paclitaxel Protein-Bound):Celgene
  • Taxotere (Docetaxel ):Sanofi
  • Cyramza (Ramucirumab):Eli Lilly
  • Gemzar (Gemcitabine):Eli Lilly
  • Zykadia (Ceritinib):Novartis
  • Opdivo (Nivolumab):Bristol-Myers Squibb
    • 作用機制
    • 收益預測
    • 趨勢等

第4章 NSCLC的研發產品線的預測

  • Alecensa (Alectinib):Roche
  • Vargatef (Nintedanib):Boehringer Ingelheim
  • AZD9291:AstraZeneca
  • Rociletinib (CO-1686):Clovis Oncology
  • Keytruda (Pembrolizumab):Merck (MSD)
  • Ganetespib (STA-9090):Synta Pharmaceuticals
  • Halaven (Eribulin):Eisai
  • Necitumumab:Eli Lilly
  • Atezolizumab (MPDL3280A):Roche

第5章 全球NSCLC市場預測

  • 全球NSCLC市場預測
  • 成長推動因素
    • 高齡化的進行
    • 標靶治療的生物標記鑑定
    • 具有力開發平台的動態盈利高的部門
    • 鱗狀細胞癌的治療這個龐大的未滿足需求的補充
  • 阻礙成長要素
    • 專利的失效、學名藥的侵蝕
    • 新藥效果低
    • 醫療預算的縮小
  • SWOT分析

第6章 主要治療區分、各主要國家的預測

  • 治療各種類市場變化與預測
    • 化療
    • EGFR、ALK抑制劑
    • VEGF/VEGFR抑制劑
    • 免疫療法
  • 主要國家市場
    • 全球市場的地區結構:成果、預測
    • 主要國家市場預測
    • 美國
    • 歐盟5國
      • 德國
      • 法國
      • 義大利
      • 英國
      • 西班牙
    • 日本
    • 金磚四國
      • 中國
      • 巴西
      • 俄羅斯
      • 印度

第7章 總論

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0207

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 133 charts - all unavailable elsewhere.

The 172-page report provides clear detailed insight into the Non-Small Cell Lung Cancer (NSCLC) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Non-Small Cell Lung Cancer (NSCLC) Drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the main therapeutic segments:
  • Chemotherapy
  • EGFR and ALK Inhibitors
  • VEGF / VEGFR Inhibitors
  • Immunotherapy

image1

  • This report provides revenue forecast to 2027 for the leading drugs in this market:
  • Alimta (pemetrexed) by Eli Lilly
  • Avastin (bevacizumab) by Roche
  • Tarceva (erlotinib) by Roche
  • Iressa (gefitinib) by AstraZeneca
  • Gilotrif (afatinib) by Boehringer Ingelheim
  • Xalkori (crizotinib) by Pfizer
  • Abraxane (paclitaxel Protein-Bound) by Celgene
  • Taxotere (docetaxel) by Sanofi
  • Cyramza (ramucirumab) by Eli Lilly
  • Zykadia (ceritinib) by Novartis
  • Opdivo (nivolumab) by Bristol-Myers Squibb
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • The US
    • Japan
    • Germany
    • France
    • Italy
    • Spain
    • The UK
    • China
    • Brazil
    • Russia
    • India
    • Rest of the World
  • This report also includes a chapter on R&D which discusses some of the most promising and prominent late-stage candidates
  • Our study includes a SWOT analysis of this industry and market
  • Our study explores the issues and forces that influence the NSCLC drugs market:
  • Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
  • Treatment protocols by stage and for patient populations - maintenance, second-line and third-line therapies
  • Regulators' views and cost-effectiveness - challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
  • Recent approval for the NSCLC indication - expanding treatment options
  • Overcoming patent expiries and competition from generic drugs
  • Identification of biomarkers for targeted therapies, advancing treatment protocols.

Visiongain's study is intended for anyone requiring commercial analyses for the Non-Small Cell Lung Cancer (NSCLC) Drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
  • 1.2 Why You Should Read this Report
  • 1.3 How this Report Delivers
  • 1.4 Main Questions Answered by this Report
  • 1.5 Who is this Report for?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to NSCLC and its Treatment

  • 2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
  • 2.2 The Three Main Histological Sub-Types of NSCLC
  • 2.3 Genetic Mutations Allow for Targeted Therapies
  • 2.4 Staging of NSCLC
  • 2.5 Treatment Protocols by Stage
    • 2.5.1 Stage 1 or 2
    • 2.5.2 Stage 3
    • 2.5.3 Stage 4: First Line-Therapy
      • 2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
      • 2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
      • 2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
    • 2.5.4 Maintenance Therapy
    • 2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2017-2027

  • 3.1 Alimta (pemetrexed) by Eli Lilly - The Leading NSCLC Therapy
    • 3.1.1 Mechanism of Action
    • 3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
    • 3.1.3 Patent Expiries
      • 3.1.3.1 'Method-Of-Use' Vitamin Dosage Regimen Patent - Alimta's Saviour from Generic Competition?
    • 3.1.4 NICE Rejects Alimta for Maintenance Therapy
    • 3.1.5 Total Alimta Revenues, 2010-2016
    • 3.1.6 Alimta for NSCLC, 2016
    • 3.1.7 Alimta for NSCLC Forecast, 2017-2027
  • 3.2 Avastin (bevacizumab) - Roche's Cancer Behemoth is a Leading Presence in NSCLC
    • 3.2.1 Mechanism of Action
    • 3.2.2 Multiple Approved Indications, but NSCLC was one of the First
    • 3.2.3 Growing Discontent with Avastin in NSCLC - Is it Cost-Effective?
    • 3.2.4 Total Avastin Revenues, 2010-2016
    • 3.2.5 Avastin for NSCLC Forecast, 2017-2027
  • 3.3 Tarceva (erlotinib) by Roche
    • 3.3.1 Mechanism of Action
    • 3.3.2 Three of Four Indications are for NSCLC
    • 3.3.3 NICE Changes Mind on Tarceva - and then Changes it Back Again
    • 3.3.4 Total Tarceva Revenues, 2010-2016
    • 3.3.5 Tarceva for NSCLC Forecast, 2017-2027
  • 3.4 Iressa (gefitinib) by AstraZeneca
    • 3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
    • 3.4.2 Iressa NSCLC Revenues, 2010-2016
    • 3.4.3 Iressa for NSCLC Forecast, 2017-2027
  • 3.5 Gilotrif (afatinib) by Boehringer Ingelheim
    • 3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
    • 3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
    • 3.5.3 Gilotrif for NSCLC Forecast, 2017-2027
  • 3.6 Xalkori (crizotinib) by Pfizer
    • 3.6.1 Mechanism of Action
    • 3.6.2 The First Approved ALK Inhibitor
    • 3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
    • 3.6.4 Xalkori NSCLC Revenues, 2012-2016
    • 3.6.5 Xalkori for NSCLC Forecast, 2017-2027
  • 3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
    • 3.7.1 Mechanism of Action
    • 3.7.2 Relatively Recent Approval for NSCLC Indication
    • 3.7.3 Finally Approved for NSCLC in the EU
    • 3.7.4 Total Abraxane Revenues, 2010-2016
    • 3.7.5 Abraxane for NSCLC Forecast, 2017-2027
  • 3.8 Taxotere (docetaxel) by Sanofi
    • 3.8.1 Mechanism of Action and Approved Indications
    • 3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
    • 3.8.3 Total Taxotere Revenues, 2010-2016
    • 3.8.4 Taxotere for NSCLC Forecast, 2017-2027
  • 3.9 Cyramza (ramucirumab) by Eli Lilly
    • 3.9.1 Mechanism of Action
    • 3.9.2 Many Approvals in Quick Succession
    • 3.9.3 Cyramza for NSCLC Forecast, 2017-2027
    • 3.10 Gemzar (gemcitabine) by Eli Lilly
  • 3.11 Zykadia (ceritinib) by Novartis
    • 3.11.1 Mechanism of Action and Recent Approval
    • 3.11.2 Zykadia for NSCLC Forecast, 2017-2027
  • 3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
    • 3.12.1 Mechanism of Action - Works With the Immune System to Fight Cancers
    • 3.12.2 Swift Approvals through FDA Priority Review Programmes
    • 3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
    • 3.12.4 Opdivo for NSCLC Forecast, 2017-2027

4. NSCLC R&D Pipeline, 2017-2027

  • 4.1 Alecensa (alectinib) by Roche
    • 4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
    • 4.1.2 Roche is Inching Closer Towards the All-Important US Approval
    • 4.1.3 Roche receives EU Approval
    • 4.1.4 Seven Ongoing Clinical Trials involving Alectinib in NSCLC
    • 4.1.5 Japanese Revenues and Future Outlook
  • 4.2 Vargatef (nintedanib) by Boehringer Ingelheim
    • 4.2.1 EU Becomes First Region to Approve Vargatef
    • 4.2.2 NICE has a Change of Heart on Vargatef
    • 4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
  • 4.3 AZD9291 by AstraZeneca
    • 4.3.1 Regulatory Approval in the US
    • 4.3.2 Regulatory Approval in the EU
    • 4.3.3 Regulatory Approval in Japan and China
    • 4.3.4 Collaboration with Roche to Develop Companion Diagnostic
    • 4.3.5 Positive Preliminary Results Presented at ASCO 2015
    • 4.3.6 Ongoing Clinical Trials Involving AZD9291 in NSCLC
  • 4.4 Rociletinib (CO-1686) by Clovis Oncology
    • 4.4.1 In a Race to Approval Against AZD9291
    • 4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
    • 4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
  • 4.5 Keytruda (pembrolizumab) by Merck (MSD)
    • 4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
    • 4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
  • 4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
    • 4.6.1 Ganetespib Mechanism of Action
    • 4.6.2 Termination of Ganetespib trial
  • 4.7 Halaven (eribulin) by Eisai
    • 4.7.1 Halaven Mechanism of Action
    • 4.7.2 US Approval for Halaven
    • 4.7.3 EU Approval for Halaven
    • 4.7.4 Clinical Trials Involving Halaven in NSCLC
  • 4.8 Necitumumab by Eli Lilly
    • 4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
    • 4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
    • 4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
  • 4.9 Atezolizumab (MPDL3280A) by Roche
    • 4.9.1 Mechanism of Action
    • 4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
    • 4.9.3 Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2017-2027

  • 5.1 The Global NSCLC Market Forecast, 2017-2027
  • 5.2 What Factors will Drive Growth in the Global NSCLC Market?
  • 5.3 Growing Ageing Population
  • 5.4 The Identification of Biomarkers for Targeted Therapies
  • 5.5 Dynamic and Lucrative Sector with Strong Pipeline
  • 5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
  • 5.7 What Factors will Restrain Growth in the Global NSCLC Market?
  • 5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
  • 5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
  • 5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
  • 5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market

  • 6.1 Therapeutic Composition of the Market in 2017 Compared to 2027
    • 6.1.1 Therapeutic Segments Forecast, 2017-2027
    • 6.1.2 Chemotherapy Segment Forecast, 2017-2027
    • 6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2017-2027
    • 6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2017-2027
    • 6.1.5 Immunotherapy Segment Forecast, 2017-2027
  • 6.2 Leading National Markets for NSCLC
    • 6.2.1 Regional Composition of the Global Market in 2017, Compared to 2027
    • 6.2.2 Leading Regional Markets for NSCLC Forecast, 2017-2027
    • 6.2.3 US NSCLC Market, 2017-2027
      • 6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
      • 6.2.3.2 US NSCLC Market Forecast, 2017-2027
    • 6.2.4 EU5 NSCLC Market, 2017-2027
      • 6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
      • 6.2.4.2 German NSCLC Market Forecast, 2017-2027
      • 6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
      • 6.2.4.4 French NSCLC Market Forecast, 2017-2027
      • 6.2.4.5 Italian NSCLC Market
      • 6.2.4.6 Italian NSCLC Market Forecast, 2017-2027
      • 6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
      • 6.2.4.8 UK NSCLC Market Forecast, 2017-2027
      • 6.2.4.9 Spanish NSCLC Market
      • 6.2.4.10 Spanish NSCLC Market Forecast, 2017-2027
    • 6.2.5 Japanese NSCLC Market
      • 6.2.5.1 Expansion of the Generics Market is a Key Factor
      • 6.2.5.2 Japanese NSCLC Market Forecast, 2017-2027
    • 6.2.6 BRIC NSCLC Market, 2017-2027
      • 6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
      • 6.2.6.2 China NSCLC Market Forecast, 2017-2027
      • 6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
      • 6.2.6.4 Brazilian NSCLC Market Forecast, 2017-2027
      • 6.2.6.5 Russian NSCLC Market: Punches Below its Weight
      • 6.2.6.6 Russian NSCLC Market Forecast, 2017-2027
      • 6.2.6.7 Indian NSCLC Market: Generics are King
      • 6.2.6.8 Indian NSCLC Market Forecast, 2017-2027

7. Conclusions from our Research and Analysis

  • 7.1 How Will Revenues Change over the Forecast Period?
  • 7.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
  • 7.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
  • 7.4 Concluding Remarks

Appendices

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 Example NSCLC First-Line Therapy Options for the Different Patient Populations
  • Table 3.1 FDA-Approved Indications for Alimta, 2004-2009
  • Table 3.2 Patent Expiries for Alimta, 2015-2022
  • Table 3.3 Total Alimta Revenues ($bn), AGR (%), CAGR (%), 2010-2016
  • Table 3.4 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.5 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.6 FDA-Approved Indications for Avastin, 2004-2014
  • Table 3.7 Total Avastin Revenues ($bn), AGR (%), CAGR (%), 2010-2016
  • Table 3.8 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.9 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.10 FDA-Approved Indications for Tarceva, 2004-2013
  • Table 3.11 Total Tarceva Revenues ($bn), AGR (%), CAGR (%), 2010-2016
  • Table 3.12 Tarceva NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.13 Tarceva for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.14 Total Iressa Revenues ($bn), 2010-2016
  • Table 3.15 Iressa NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.16 Iressa for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.17 Gilotrif NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.18 Gilotrif for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.19 Total Xalkori Revenues ($bn), AGR (%), CAGR (%), 2012-2016
  • Table 3.20 Xalkori NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.21 Xalkori for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.22 FDA-Approved Indications for Abraxane, 2005-2013
  • Table 3.23 Total Abraxane Revenues ($bn), AGR (%), CAGR (%), 2010-2016
  • Table 3.24 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.25 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.26 FDA-Approved Indications for Taxotere, 1999-2006
  • Table 3.27 Total Taxotere Revenues ($bn), AGR (%), CAGR (%), 2010-2016
  • Table 3.28 Taxotere NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.29 Taxotere for NSCLC Forecast: Revenues ($bn), AGR (%),CAGR (%), 2021-2027
  • Table 3.30 FDA-Approved Indications for Cyramza, 2014-2015
  • Table 3.31 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.32 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.33 FDA-Approved Indications for Abraxane, 1996-2006
  • Table 3.34 Zykadia NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.35 Zykadia for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 3.36 Opdivo NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 3.37 Opdivo for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 4.1 Currently Ongoing Clinical Trials Involving Alectinib in NSCLC
  • Table 4.2 Selected Ongoing Clinical Trials Involving Vargatef in NSCLC
  • Table 4.3 Selected Ongoing Clinical Trials Involving AZD9291 in NSCLC
  • Table 4.4 Ongoing Clinical Trials Involving Rociletinib in NSCLC
  • Table 4.5 Selected Ongoing Clinical Trials Involving Keytruda in NSCLC
  • Table 4.6 Ongoing Clinical Trials Involving Ganetespib in NSCLC
  • Table 4.7 Clinical Trials Involving Halaven in NSCLC
  • Table 4.8 Selected Ongoing Clinical Trials Involving Necitumumab in NSCLC
  • Table 4.9 Ongoing Clinical Trials Involving Atezolizumab in NSCLC
  • Table 5.1 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2020
  • Table 5.2 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 6.1 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.2 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.3 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.4 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.6 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.7 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.8 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.9 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
  • Table 6.10 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.11 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.12 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.13 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.14 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.15 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%),2014-2020
  • Table 6.16 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
  • Table 6.17 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.18 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.19 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.20 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027
  • Table 6.21 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.22 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
  • Table 6.23 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
  • Table 6.24 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
  • Table 6.25 Japanese NSCLC Market:Revenues ($bn), AGR (%),CAGR (%),Market Share (%), 2014-2020
  • Table 6.26 Japanese NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2021-2027
  • Table 6.27 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
  • Table 6.28 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
  • Table 6.29 Brazilian NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2014-2020
  • Table 6.30 Brazilian NSCLC Market: Revenues ($bn),AGR (%),CAGR (%),Market Share (%), 2021-2027
  • Table 6.31 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2014-2020
  • Table 6.32 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%),Market Share (%), 2021-2027
  • Table 6.33 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
  • Table 6.34 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2027

List of Figures

  • Figure 2.1 Example Adjuvant Chemotherapy Regimens for NSCLC in Stage 1 or Stage 2
  • Figure 2.2 Example Chemotherapy Regimens for Use in Concurrent Chemotherapy / Radiation in Stage 3 NSCLC
  • Figure 2.3 Example Chemotherapy Regimens for use in Stage 4 NSCLC
  • Figure 3.1 Total Alimta Revenues ($bn), 2010-2016
  • Figure 3.2 Alimta for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.3 Total Avastin Revenues ($bn), 2010-2016
  • Figure 3.4 Avastin for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.5 Total Tarceva Revenues ($bn), 2010-2016
  • Figure 3.6 Tarceva for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.7 Total Iressa Revenues ($bn), 2010-2016
  • Figure 3.8 Iressa Revenues Regional Breakdown: Revenues ($bn), Market Share (%), 2016
  • Figure 3.9 Iressa for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.10 Gilotrif for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.11 Total Xalkori Revenues ($bn), 2012-2016
  • Figure 3.12 Xalkori for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.13 Total Abraxane Revenues ($bn), 2010-2016
  • Figure 3.14 Abraxane for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.15 Total Taxotere Revenues ($bn), 2010-2016
  • Figure 3.16 Taxotere for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.17 Cyramza for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.18 Zykadia for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 3.19 Opdivo for NSCLC Forecast: Revenues ($bn), 2017-2027
  • Figure 5.1 Global NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 5.2 SWOT Analysis of Global NSCLC Market, 2017
  • Figure 6.1 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2017
  • Figure 6.2 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2027
  • Figure 6.3 Therapeutic Segments within the NSCLC Market: Revenues ($bn), 2017-2027
  • Figure 6.4 Chemotherapy Segment: Revenues ($bn), 2017-2027
  • Figure 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), 2017-2027
  • Figure 6.6 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), 2017-2027
  • Figure 6.7 Immunotherapy Segment: Revenues ($bn), 2017-2027
  • Figure 6.8 Regional Composition of the Global NSCLC Market: Revenues ($bn),Market Share (%), 2017
  • Figure 6.9 Regional Composition of the Global NSCLC Market: Revenues ($bn),Market Share (%), 2027
  • Figure 6.10 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), 2017-2027
  • Figure 6.11 US NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.12 German NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.13 French NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.14 Italian NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.15 UK NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.16 Spanish NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.17 Japanese NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.18 Chinese NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.19 Brazilian NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.20 Russian NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 6.21 Indian NSCLC Market Forecast: Revenues ($bn), 2017-2027
  • Figure 7.1 Global NSCLC Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2017-2027
  • Figure 7.2 Breakdown by Submarket: Revenues ($bn), 2017-2027
  • Figure 7.3 Leading National Markets: Revenues ($bn), 2017
  • Figure 7.4 Leading National Markets: Revenues ($bn), 2027

Companies Listed

  • Abbott
  • Abraxis
  • Actavis
  • Amgen
  • Apotex
  • AstraZeneca
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Chiba University Hospital (Japan)
  • Chugai
  • Clovis Oncology
  • Eisai
  • Eli Lilly
  • EMD Serono
  • Hospira
  • Merck (MSD)
  • Merck KGaA
  • Novartis
  • Oanda
  • Pfizer
  • Qiagen
  • Roche
  • Roche Molecular Systems Inc
  • Sanofi
  • Swiss Re
  • Synta Pharmaceuticals
  • Teva

Organizations Mentioned in the Report

  • American Cancer Society
  • American Society of Clinical Oncology
  • Committee for Medicinal Products for Human Use (CHMP)
  • European Commission
  • European Medicines Agency (EMA)
  • European Union (EU)
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • National Comprehensive Cancer Network (NCCN)
  • Oncologic Drugs Advisory Committee (ODAC)
  • The Court of Appeal (England)
  • The European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • The High Court (England)
  • The National Health Service (NHS, England)
  • The National Institute for Health and Care Excellence (NICE)
  • US Court of Appeals
  • US Food and Drug Administration (FDA)
  • World Health Organization (WHO)
Back to Top